ライフサイエンスコーパス: dexamethasone

1 antibodies (Infliximab) or glucocorticoids (Dexamethasone).

2 ive daily fractions) or OSC alone (including dexamethasone).

3 e subjected to corticosteroid treatment with dexamethasone.

4 ades at day 28 comparing XG-102 900 mug with dexamethasone.

5 amethasone, and 63% versus lenalidomide plus dexamethasone.

6 xpansion) in combination with bortezomib and dexamethasone.

7 hose produced by the steroids clobetasol and dexamethasone.

8 anti-MM agents lenalidomide, pomalidomide or dexamethasone.

9 rt, the sensitizing effects of rapamycin and dexamethasone.

10 thalidomide monotherapy and thalidomide plus dexamethasone.

11 ansient edema that required short courses of dexamethasone.

12 us injection of the synthetic corticosteroid dexamethasone.

13 se (MTD) of isatuximab with lenalidomide and dexamethasone.

14 387) or placebo (n=381), plus bortezomib and dexamethasone.

15 nce of psychopathology was not influenced by dexamethasone.

16 ntly diminished the proapoptotic response to dexamethasone.

17 vitrectomized eyes treated with slow-release dexamethasone.

18 is initiated by the synthetic corticosteroid dexamethasone.

19 same chemotherapy regimen of bortezomib and dexamethasone.

20 y of allergic airway inflammation (AAI) with dexamethasone.

21 0 (95% CI, 1.18-3.41) for ciprofloxacin plus dexamethasone.

22 unoglobulin (hIVIG), (2) fluoxetine, and (3) dexamethasone.

23 2s from asthmatic patients were resistant to dexamethasone.

24 of MUC4 in the anti-inflammatory effects of dexamethasone.

25 GR) by using cell-impermeable BSA-conjugated dexamethasone.

26 inflammation, were not counter-regulated by dexamethasone.

27 el that can be prevented by folinic acid and dexamethasone.

28 This effect was not seen with adjunctive dexamethasone.

29 tane 25 mg daily, with 10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL oral solution (swish for 2

30 s for both XG-102 groups were noninferior to dexamethasone (-0.054 anterior cell grade [95% confidenc

31 600 mg 6 hours after the first dose; 2) 4 mg dexamethasone 1 hour before surgery and another 4 mg 6 h

32 alidomide 25 mg daily on days 1-14 plus oral dexamethasone 20 mg daily on days 1, 2, 4, 5, 8, 9, 11,

33 ib 1.3 mg/m(2), and oral thalidomide 100 mg, dexamethasone 20 mg, and panobinostat 10, 15, or 20 mg (

34 thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or bo

35 Dexamethasone (20 mg oral or intravenous infusion) was g

36 avenous bolus or subcutaneous injection) and dexamethasone (20 mg oral or intravenous infusion).

37 g per square meter of body-surface area) and dexamethasone (20 mg) alone (control group) or in combin

38 riocular conjunctival fornix injections of a dexamethasone-21-acetate (DEX-Ac) formulation.

39 0% completed the intervention), 288 received dexamethasone; 277, placebo.

40 In this study, we administered dexamethasone 4 h before EXT training and then examined

41 on days 1-21 of 28-day cycles with low-dose dexamethasone 40 mg (20 mg for patients aged >75 years)

42 tion with lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (QW), in patients with relapsed/refr

43 daily for 21 days of each 28-day cycle, and dexamethasone 40 mg weekly.

44 ks, pomalidomide 4 mg daily for 21 days, and dexamethasone 40 mg weekly.

45 s in combination with lenalidomide 25 mg and dexamethasone 40 mg.

46 (1.0 mg/m(2) on days 1, 8, 15, and 22), and dexamethasone (40 mg by mouth on days 1, 8, 15, and 22)

47 [in all other cohorts] once daily) and oral dexamethasone (40 mg weekly).

48 22) for 4 additional 35-day cycles, with IV dexamethasone (40 mg) and IV rituximab (375 mg/m(2)) on

49 Patients received dexamethasone (40 mg) on days 1, 8, 15, and 22; dexameth

50 artial response after 3 cycles received oral dexamethasone (40 mg, days 1-4) from cycle 4.

51 g/day orally on days 1-21 of each cycle) and dexamethasone (40 mg/week).

52 e risk of progression or death by 87% versus dexamethasone, 81% versus bortezomib plus dexamethasone,

53 r overall survival (OS) in the total cohort (dexamethasone, 90.3 +/- 0.7%; prednisone, 90.5 +/- 0.7%)

54 Unlike dexamethasone (a nonparticulate steroid solution), salin

55 ing macrophage recruitment or administrating dexamethasone, a commonly used glucocorticoid to prevent

56 ry stimulation and subsequent treatment with dexamethasone, a powerful antiphlogistic drug.

57 inction (EXT) of conditioned freezing, using dexamethasone administered systemically which is known t

58 examethasone (VRd group) or lenalidomide and dexamethasone alone (Rd group).

59 lophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dos

60 ted or were systemically treated with either dexamethasone, aminophylline, or a combination of the tw

61 of VEGF, which promotes vascularization, or dexamethasone, an anti-inflammatory agent.

62 drug doses of P-III were reduced by 30% for dexamethasone and 50% for vincristine, doxorubicin, and

63 ent-free survival rates of 83.9 +/- 0.9% for dexamethasone and 80.8 +/- 0.9% for prednisone (P = .024

64 Treatment with dexamethasone and dasatinib also impaired engraftment of

65 ent between patient groups after exposure to dexamethasone and FCS, and these were associated with bi

66 ASMCs were exposed to dexamethasone and FCS.

67 gation of the normal pro-apoptotic effect of dexamethasone and fluticasone furoate.

68 further interpret the effects of adjunctive dexamethasone and glycerol using clinical trial data fro

69 (9.3%) and 69 patients (12.3%) who received dexamethasone and in 66 patients (11.7%) and 78 patients

70 hand, increased blood vessel formation when dexamethasone and l-DOPA were administered simultaneousl

71 naling, and conferred relative resistance to dexamethasone and lenalidomide treatments.

72 yeloma (R/R MM) after a long period in which dexamethasone and melphalan had been the standard treatm

73 xtracellular traps, an event unsuppressed by dexamethasone and possibly contributing to the steroid-u

74 with intravitreal ganciclovir, intravitreal dexamethasone and systemic prednisone, the change in vis

75 ty as a single agent and in combination with dexamethasone and vincristine.

76 repared monocyte-derived tolDCs modulated by dexamethasone and vitamin D2 from 31 T1D patients with o

77 ) bortezomib monotherapy and bortezomib plus dexamethasone, and (2) thalidomide monotherapy and thali

78 us dexamethasone, 81% versus bortezomib plus dexamethasone, and 63% versus lenalidomide plus dexameth

79 of patients in 2005-2009 received melphalan-dexamethasone, and 64% of patients in 2000-2004 received

80 ls was inhibited by the uPA inhibitor UK122, dexamethasone, and a FOXO inhibitor.

81 ith neurolisteriosis treated with adjunctive dexamethasone, and also determined the time window for f

82 limited effect in mice treated with saline, dexamethasone, and cortivazol (20.3, 21.3, and 27.5 mm/s

83 per millimeter in mice treated with saline, dexamethasone, and cortivazol, respectively; P < .003).

84 enhanced chemosensitization to doxorubicin, dexamethasone, and ibrutinib.

85 s when used with small doses of the steroid, dexamethasone, and promotes the tissue healing process.

86 epileptic drug (phenytoin or carbamazepine), dexamethasone, and ranitidine.

87 e efficacy of the combination of bortezomib, dexamethasone, and rituximab (BDR) in 59 previously untr

88 By application of dexamethasone, anthocyanin formation was induced within

89 pharmacological (methionine sulfoximine and dexamethasone) approaches to modulate GS activity, we fu

90 Combination studies using pomalidomide and dexamethasone are now underway.

91 to 21 (cohort 3) every 28 days, with weekly dexamethasone at a dose of 20 mg.

92 recruitment to be essentially unaffected by dexamethasone at the CXCL10 promoter or at the promoters

93 Interventions included anti-IL-33 or dexamethasone at various stages of disease.

94 We aimed to assess dexamethasone-based mouthwash for prevention of stomatit

95 ib and dexamethasone (EBd) or bortezomib and dexamethasone (Bd) until disease progression/unacceptabl

96 ICP0) and bICP4 expression, is stimulated by dexamethasone because it contains two glucocorticoid rec

97 hasone (carfilzomib group) or bortezomib and dexamethasone (bortezomib group) through a blocked rando

98 xazomib in combination with lenalidomide and dexamethasone can be safely administered to patients wit

99 ly assigned (1:1) to receive carfilzomib and dexamethasone (carfilzomib group) or bortezomib and dexa

100 of recovery in patients' receiving PILA with dexamethasone compared with control for a TEP-IHR surger

101 ith acute sore throat, a single dose of oral dexamethasone compared with placebo did not increase the

102 ation of the glucocorticoid receptor agonist dexamethasone-compared with placebo-during cardiac surge

103 Dexamethasone could be added on progression during treat

104 circadian rhythm (10 mg/m(2)/d) during both dexamethasone courses.

105 of immunochemotherapy induction (rituximab, dexamethasone, cytarabine, and a platinum derivative [R-

106 ease in mRNA levels of TGF-beta group, while dexamethasone (DEX) decreased TGF-beta group mRNA levels

107 T biomarkers for DME treated by intravitreal dexamethasone (DEX) implant.

108 To evaluate the efficacy and safety of dexamethasone (DEX) implants in paediatric patients with

109 ocorticoid receptor (GR) and the efficacy of dexamethasone (Dex) in human keratinocytes (HaCaT cells)

110 The potent GC, dexamethasone (Dex) increased the secretory protein load

111 orb and modulate the release of a model drug dexamethasone (Dex) to promote the osteogenic differenti

112 age transcriptional and chromatinscapes with Dexamethasone (Dex) treatment before or after stimulatio

113 to proliferate or to differentiate following dexamethasone (Dex) treatment in vitro, as evidenced by

114 Dexamethasone (DEX), a synthetic ligand for glucocortico

115 Glucocorticoids (GCs), including dexamethasone (dex), are a central component of combinat

116 We subsequently treated the cells with dexamethasone (Dex), routinely used to induce commitment

117 its inhibition attenuates atrophy induced by dexamethasone (Dex), TNF-alpha and H2O2 treatment.

118 ation on other classes of nuclear receptors, dexamethasone (Dex)-induced trans-repression of the estr

119 a cell-based GR activity assay that measures Dexamethasone (Dex)-mediated NF-kappaB repression, we ha

120 corticosterone in mice) and synthetic [e.g., dexamethasone (Dex)] hormone.

121 Here, we show that dexamethasone (Dexa) and rapamycin (Rapa), commonly admi

122 Although dexamethasone did not repress IL1B-induced IRF1 protein

123 Treatment with anti-IL-33 or dexamethasone diminished exacerbation severity, and anti

124 Treatment with dexamethasone downregulated most cytokines and proteases

125 ented with T3 (triiodothyronine) and/or Dex (dexamethasone) during days 16 to 30 followed by single-c

126 RMM) received elotuzumab with bortezomib and dexamethasone (EBd) or bortezomib and dexamethasone (Bd)

127 Dexamethasone effect on ST2 transcript expression was an

128 n vitro GR activity ranged from 39 to 155 ng dexamethasone-equivalent/L (ng Dex-EQ/L) in the secondar

129 nts or cell lines treated with the GR ligand dexamethasone exhibited robust induction of Brk mRNA and

130 We conclude that dexamethasone exposure during pregnancy provides long-la

131 We studied how gestational dexamethasone exposure influences the AD-like phenotype

132 astoma dataset to explore the association of dexamethasone exposure with outcome.

133 the end of ocular surgery is noninferior to dexamethasone eye drops in the treatment of postoperativ

134 d safety of XG-102 (brimapitide) compared to dexamethasone eye drops in the treatment of postoperativ

135 approved in combination with bortezomib and dexamethasone for patients with relapsed multiple myelom

136 randomized clinical trial that investigated dexamethasone for the prophylaxis of pain flare after ra

137 e, and Dexamethasone Versus Lenalidomide and Dexamethasone for the Treatment of Patients With Relapse

138 pose a RP2D of 45 mg/m(2) (80 mg) plus 20 mg dexamethasone given twice weekly.

139 At 24 hours, 65 participants (22.6%) in the dexamethasone group and 49 (17.7%) in the placebo group

140 4 events, P=0.01), with more patients in the dexamethasone group having grade 3 or 4 infection (48 vs

141 nical adverse events were more common in the dexamethasone group than in the placebo group (667 vs. 4

142 At 48 hours, 102 participants (35.4%) in the dexamethasone group vs 75 (27.1%) in the placebo group a

143 nce in cerebrospinal fluid was slower in the dexamethasone group.

144 ed to the XG-102 90 mug, XG-102 900 mug, and dexamethasone groups, respectively.

145 ombination of venetoclax with bortezomib and dexamethasone has an acceptable safety profile and promi

146 Carfilzomib with dexamethasone has shown promising activity in patients i

147 e inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the sett

148 Pembrolizumab, pomalidomide, and low-dose dexamethasone have acceptable safety and durable respons

149 cell recruitment and cytokine production by dexamethasone impairs proliferation of progenitor horizo

150 teroids, including triamcinolone (4) and the dexamethasone implant (2).

151 A at baseline and 60 days after intravitreal dexamethasone implant (IVDEX).

152 the hypothesis that adjunctive slow-release dexamethasone implant (Ozurdex; Allergan Inc, Irvine, CA

153 es with DME treated with 0.7 mg intravitreal dexamethasone implant and minimum 18-month follow-up.

154 A slow-release dexamethasone implant did not improve the primary anatom

155 early visual acuity response to intravitreal dexamethasone implant therapy in diabetic macular edema

156 odes for aflibercept, triamcinolone, and the dexamethasone implant.

157 emia that did not recover after intravitreal dexamethasone implant.

158 occlusion and initially low visual acuity, a dexamethasone implantation can lead to an important redu

159 Four weeks after dexamethasone implantation visual acuity remained stable

160 multifactorial molecular mechanism by which dexamethasone implants reduce edema and suggest that add

161 with dexamethasone than with bortezomib and dexamethasone in an interim analysis.

162 lpha was insensitive to both fluticasone and dexamethasone in ASM cells from severe asthmatic compare

163 depth profiles of the antiinflammatory drug dexamethasone in human skin, we model the time-dependent

164 ffect was observed between aminophylline and dexamethasone in maintaining HDAC2 expression levels, pr

165 o date evaluating pomalidomide plus low-dose dexamethasone in patients with RRMM, further confirming

166 nation of ricolinostat with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma

167 al compared with placebo plus bortezomib and dexamethasone in the phase 3 PANORAMA 1 trial.

168 Co-delivery of both autoantigen and dexamethasone increased B-cell populations and antibody

169 In contrast, the addition of dexamethasone increased the ORR with all responses of >/

170 apy with combined bortezomib, melphalan, and dexamethasone independently prolonged time to second-lin

171 Here, we show that in vitro treatment with dexamethasone induced a rapid increase of KLF15 expressi

172 expression at 4-6 h, silencing of IL1B plus dexamethasone-induced DUSP1 significantly reduced IRF1 e

173 We applied the dexamethasone-induced gene signature to The Cancer Genom

174 -driven reporter activity without disrupting dexamethasone-induced nuclear translocation of GR.

175 s, podocyte-specific loss of Klf15 abrogated dexamethasone-induced podocyte recovery.

176 During dexamethasone-induced reactivation from latency, mRNA ex

177 Dexamethasone induces the recruitment of ACTN4 and GR to

178 was introduced in tomato under control of a dexamethasone-inducible promoter.

179 Dexamethasone inhibited (P = .04) chemoattractant recept

180 Dexamethasone inhibited c-Fos, inhibitor of DNA binding

181 Dexamethasone inhibited type 2 cytokine production by bl

182 ry at 1 month, whereas the use of periocular dexamethasone injections (cRR, 0.05 [0.02-0.6]; P = 0.01

183 Groups GIOP + EP and ATV received 7 mg/kg dexamethasone intramuscularly once per week for 5 weeks,

184 The rate of endophthalmitis following dexamethasone intravitreal implant (DEX) has varied in l

185 Dexamethasone intravitreal implant injection was given 1

186 ee survival (PFS) with ixazomib-lenalidomide-dexamethasone (IRd) compared with placebo-lenalidomide-d

187 Dexamethasone is a key component in the treatment of ped

188 Lenalidomide plus dexamethasone is a reference treatment for patients with

189 Bortezomib with dexamethasone is a standard treatment option for relapse

190 -ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at

191 at isatuximab combined with lenalidomide and dexamethasone is active and tolerated in heavily pretrea

192 conclude that selinexor in combination with dexamethasone is active in heavily pretreated MM and pro

193 bination of netupitant and palonosetron plus dexamethasone is an additional treatment option in this

194 Steroidal dexamethasone is as effective as non-steroidal ibuprofen

195 yeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidom

196 he effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethason

197 ACTN4 by shRNA in HPCs significantly reduces dexamethasone-mediated induction of GR target genes and

198 ACTN4 results in reduced GR interaction and dexamethasone-mediated transactivation of a GRE reporter

199 The synthetic glucocorticoids (GCs) dexamethasone, mometasone furoate, and triamcinolone ace

200 After 8 weeks, dexamethasone mouthwash could be continued for up to eig

201 ve advanced breast cancer who were not given dexamethasone mouthwash for prevention of stomatitis).

202 xemestane and at least one confirmed dose of dexamethasone mouthwash) versus historical controls from

203 Single oral dose of 10 mg of dexamethasone (n = 293) or identical placebo (n = 283).

204 In terms of repression by dexamethasone, neither silencing of DUSP1, silencing of

205 and vomiting; a recommendation to administer dexamethasone on day 1 only for adults who receive anthr

206 toma was used to characterize the effects of dexamethasone on tumour cell proliferation and death, an

207 ide once a day for days 1-21 plus 40 mg oral dexamethasone once a day on days 1, 8, 15, and 22.

208 SRI31277 was as effective as dexamethasone or bortezomib, and SRI31277 combined with

209 corticosteroid therapy that included either dexamethasone or prednisone.

210 To this end, female mice received dexamethasone or vehicle during the entire pregnancy tim

211 Combination treatment of ibrutinib with dexamethasone or vincristine demonstrated synergistic ac

212 .40], p=0.002) or those receiving adjunctive dexamethasone (OR 4.58 [1.50-13.98], p=0.008).

213 n plus hydrocortisone, or ciprofloxacin plus dexamethasone) or neomycin plus hydrocortisone.

214 d a trial drug (ie, bortezomib, thalidomide, dexamethasone, or panobinostat).

215 INTERPRETATION: Prophylactic use of dexamethasone oral solution substantially reduced the in

216 eived an injection of 0.7 mg of slow-release dexamethasone (Ozurdex) at the time of (1) vitrectomy su

217 the safety and efficacy of pomalidomide and dexamethasone (PDex) in patients with AL amyloidosis who

218 ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group).

219 one (IRd) compared with placebo-lenalidomide-dexamethasone (placebo-Rd).

220 ) to optimal supportive care (OSC) including dexamethasone plus WBRT (20 Gy in five daily fractions)

221 Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with r

222 Incorporation of dexamethasone prevented further dose-limiting CLS.

223 n siRNA-MUC4 BEAS-2B airway epithelial cells dexamethasone produced higher anti-inflammatory effects,

224 acerbation severity, and anti-IL-33, but not dexamethasone, promoted antiviral interferon expression

225 Cohorts B and C received dexamethasone prophylaxis against capillary leak syndrom

226 of blinatumomab by continuous infusion, with dexamethasone prophylaxis, in patients with relapsed/ref

227 ompares efficacy of preemptive ibuprofen and dexamethasone protocols for pain prevention or control a

228 nd efficacy of pomalidomide, bortezomib, and dexamethasone (PVD) combination in patients with relapse

229 dnisone (VMP) and lenalidomide plus low-dose dexamethasone (Rd) administered in a sequential or an al

230 dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR

231 ultiple myeloma has been either lenalidomide-dexamethasone (RD) or bortezomib-dexamethasone (VD) but

232 lidomide (CPR) or lenalidomide plus low-dose dexamethasone (Rd).

233 As expected, dexamethasone reduced blood vessel formation in the CAM.

234 enance therapy was dasatinib and vincristine/dexamethasone reinductions for 18 months followed by das

235 Interestingly, dexamethasone removal did not reverse YFP inhibition.

236 Daratumumab plus lenalidomide/dexamethasone resulted in rapid, deep, durable responses

237 e addition of bortezomib to lenalidomide and dexamethasone resulted in significantly improved progres

238 e addition of bortezomib to lenalidomide and dexamethasone resulted in significantly improved progres

239 In clinical practice, dexamethasone retreatment may be required earlier than 6

240 ion of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton tyrosine kinase

241 Dexamethasone-rituximab-cyclophosphamide is an alternati

242 n therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this population have raised quest

243 combination of lenalidomide, bortezomib, and dexamethasone (RVD) with or without autologous stem-cell

244 ombination of daratumumab, lenalidomide, and dexamethasone seems to be the best treatment option.

245 Panobinostat plus bortezomib and dexamethasone significantly increased median progression

246 Ibuprofen and dexamethasone significantly reduced pain (Kruskal-Wallis

247 For dexamethasone, skin barrier function is shown to rely on

248 er day for 21 days with placebo, placebo, or dexamethasone solution, respectively.

249 Dexamethasone stimulates lytic cycle viral gene expressi

250 Anti-IL-33 or dexamethasone suppressed the magnitude of type 2 inflamm

251 pathways, as a function of both fear EXT and dexamethasone suppression of the HPA axis.

252 ention (RET) 24 h later to determine whether dexamethasone suppression rescued EXT deficits.

253 docrine function (diurnal salivary cortisol, dexamethasone suppression), cognition (neuropsychologica

254 carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in

255 e II in airway epithelial cells treated with dexamethasone, TNF, or both using chromatin immunoprecip

256 ich might partner well with lenalidomide and dexamethasone to enhance their efficacy in relapsed or r

257 Our observation that the ability of dexamethasone to modulate gene expression in airway epit

258 Dexamethasone to prevent bronchopulmonary dysplasia in v

259 scriptional co-regulator that modulates both dexamethasone-transactivated and -transrepressed genes i

260 ruitment of ACTN4 and GR to putative GREs in dexamethasone-transactivated promoters, SERPINE1, ANGPLT

261 nst bone mass loss in the ovariectomized and dexamethasone treated rat osteoporosis model.

262 (controls) were compared with offspring from dexamethasone-treated 3 x Tg later in life for their mem

263 ximine-treated mice to approximately 500% in dexamethasone-treated mice (control mice, 100%), without

264 Compared with controls, offspring from dexamethasone-treated mothers displayed improvement in t

265 he genes that are significantly regulated in dexamethasone-treated podocytes compared to vehicle-trea

266 pathologic consequences in the thymus after dexamethasone treatment and in advanced atherosclerotic

267 Dexamethasone treatment completely inhibited all feature

268 response of cord blood mononuclear cells to dexamethasone treatment in culture (P = .018).

269 Dexamethasone treatment produced dose-dependent enhancem

270 Dexamethasone treatment worsened motor impairment, incre

271 n protein expression in TG neurons 6 h after dexamethasone treatment.

272 rring in the 45 mg/m(2) selinexor plus 20 mg dexamethasone twice weekly cohort (ORR = 50%).

273 ved selinexor at 45 or 60 mg/m(2) with 20 mg dexamethasone, twice weekly in 28-day cycles, or selinex

274 Dexamethasone up-regulated sST2 transcription through in

275 Mechanistically, dexamethasone upregulated ILC2 expression of IL-7 recept

276 % CI 0.90-1.26), overall quality of life, or dexamethasone use between the two groups.

277 ance), and the vincristine, doxorubicin, and dexamethasone (VAD) group of the HOVON65/GMMG-HD4 trial

278 enalidomide-dexamethasone (RD) or bortezomib-dexamethasone (VD) but it is changing rapidly for 2 reas

279 R-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone for

280 y CD19-DE and cytoreduction by chemotherapy (dexamethasone, vincristine, PEG-asparaginase) resulted i

281 luding 30 weeks of asparaginase exposure and dexamethasone/vincristine pulses) compared with historic

282 reatment of bortezomib with lenalidomide and dexamethasone (VRd group) or lenalidomide and dexamethas

283 , 4, 8, and 11 of 3-week cycles; concomitant dexamethasone was allowed with schedule B).

284 In this work, dexamethasone was co-delivered with autoantigen (PLP) in

285 Responsiveness to the glucocorticoid dexamethasone was determined.

286 Isatuximab-lenalidomide-dexamethasone was generally well tolerated with only 1 d

287 bortezomib was administered once a week, and dexamethasone was given on the days of and following bor

288 malidomide was administered continuously and dexamethasone was given once per week at a dose of 20 or

289 ombination of daratumumab, lenalidomide, and dexamethasone was identified as the best treatment.

290 immune response via cytokines revealed that dexamethasone was important for shifting the immune resp

291 anobinostat over placebo with bortezomib and dexamethasone was modest.

292 amethasone (40 mg) on days 1, 8, 15, and 22; dexamethasone was omitted on day 22 for cycles 9+.

293 The benefit of dexamethasone was partially counterbalanced by a signifi

294 The difference between XG-102 90 mug and dexamethasone was statistically significant (P = .013).

295 Intravitreal dexamethasone was used in 50 of 63 (79%) eyes.

296 At 24 hours, participants receiving dexamethasone were not more likely than those receiving

297 gluconeogenic gene response to glucagon and dexamethasone, whereas constitutively active YAP suppres

298 ression of CXCL10 was largely insensitive to dexamethasone, whereas other DUSP1-enhanced, IRF1-depend

299 with IL-4 display an increased resistance to dexamethasone, whereas the inhibition of IL-4 signaling

300 ta indicated that the co-delivery of PLP and dexamethasone with a water-in-oil emulsion is effective

301 e addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival an